Sitala Bio Ltd develops anti-inflammatory medications that target chronic inflammation in neurodegenerative diseases and cancer by enhancing the immune system's ability to clear toxins from the brain. Their approach aims to slow the progression of conditions such as Parkinson's and Alzheimer's by addressing the dysfunction of immune cells like microglia and astrocytes.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic, low-grade inflammation, driven by immune system dysfunction, plays a significant role in the progression of neurodegenerative diseases like Parkinson's and Alzheimer's. Dysfunction of immune cells in the brain impairs the clearance of toxins, such as amyloid, contributing to disease advancement.
Solution
Sitala Bio Ltd. is developing anti-inflammatory medications designed to treat neurodegenerative and inflammatory diseases by targeting the root causes of harmful inflammation. Their therapeutic approach focuses on enhancing the immune system's ability to clear toxins from the brain, addressing the dysfunction of immune cells like microglia and astrocytes. By blocking the initiation and progression of harmful inflammation, Sitala Bio aims to treat both the symptoms and the underlying causes of these diseases. This approach has the potential to slow the progression of conditions such as Parkinson's and Alzheimer's.
Target Audience
The primary target audience includes individuals suffering from neurodegenerative diseases such as Parkinson's and Alzheimer's, as well as those affected by systemic inflammatory diseases.
Features
- Medications designed to target chronic, low-grade inflammation.
- Focus on enhancing the immune system's ability to clear toxins from the brain.
- Aims to address dysfunction of immune cells such as microglia and astrocytes.